600664.SHG Harbin Pharmaceutical Group Co Ltd
- Market cap
- CNY 14.6B
- P/E
- 23.2x
- P/B
- 2.19x
- ROE
- 12.7%
- Dividend yield
- 0.23%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600664.SHG undervalued?
Graham number600664.SHG trades 50.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Harbin Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Harbin Pharmaceutical Group Co Ltd yet.
Harbin Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Harbin Pharmaceutical Group Co Ltd
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, antiviral and anti-infective, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supp…
Full company profileHarbin Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Harbin Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.1B | 12.0B | 10.8B | 11.8B | 10.8B | 12.8B | 13.8B | 15.5B | 16.2B | 16.0B | 16.5B |
| Gross Profit | 3.70B | 3.11B | 2.90B | 2.80B | 2.25B | 2.98B | 3.36B | 4.01B | 4.52B | 4.15B | 4.32B |
| Operating Income | 997M | 656M | 527M | 278M | -942M | 642M | 696M | 660M | 890M | 731M | 1.11B |
| EBITDA | 1.41B | 984M | 882M | 550M | -434M | 717M | 821M | 878M | 1.07B | 924M | 1.08B |
| Net Income | 788M | 407M | 346M | 55.8M | -1.08B | 371M | 465M | 395M | 629M | 362M | 800M |
| EPS | 0.31 | 0.16 | 0.14 | 0.02 | -0.43 | 0.15 | 0.18 | 0.16 | 0.25 | 0.14 | 0.32 |
| Balance Sheet | |||||||||||
| Total Assets | 15.1B | 13.7B | 11.9B | 12.5B | 11.8B | 12.8B | 13.4B | 14.1B | 14.6B | 14.3B | 14.9B |
| Total Liabilities | 6.75B | 6.22B | 5.62B | 6.56B | 7.86B | 8.42B | 8.48B | 8.69B | 8.53B | 7.83B | 7.81B |
| Shareholders' Equity | 7.85B | 7.05B | 5.87B | 5.46B | 3.48B | 3.85B | 4.33B | 4.72B | 5.35B | 5.69B | 6.30B |
| Cash & Short-term Investments | 4.64B | 3.51B | 2.05B | 676M | 897M | 1.59B | 2.43B | 3.06B | 3.63B | 3.44B | 3.27B |
| Total Debt | 148M | 262M | 254M | 673M | 1.77B | 2.31B | 2.16B | 1.72B | 1.62B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.78B | 149M | 693M | -285M | -728M | -162M | 622M | 950M | 792M | 440M | - |
| Capital Expenditure | 107M | 102M | 114M | 39.0M | 118M | 76.7M | 89.6M | 86.5M | 101M | 151M | 131M |
| Free Cash Flow | 2.67B | 47.2M | 579M | -324M | -846M | -239M | 532M | 863M | 692M | 289M | 36.6M |
| Ratios | |||||||||||
| ROE | 10.0% | 5.8% | 5.9% | 1.0% | -31.0% | 9.6% | 10.7% | 8.4% | 11.8% | 6.4% | 12.7% |
| ROA | 5.2% | 3.0% | 2.9% | 0.4% | -9.1% | 2.9% | 3.5% | 2.8% | 4.3% | 2.5% | 5.4% |
| Net Profit Margin | 5.6% | 3.4% | 3.2% | 0.5% | -10.0% | 2.9% | 3.4% | 2.6% | 3.9% | 2.3% | 4.9% |
| Debt to Equity | 0.02x | 0.04x | 0.04x | 0.12x | 0.51x | 0.60x | 0.50x | 0.36x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Harbin Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 0.23%
- Forward dividend
- -
- Payout ratio
- 9.2%
- Ex-dividend date
- May 4, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 33.3M | 0.01 | 9.2% |
| 2024 | CNY 47.1M | 0.02 | 7.5% |
| 2023 | CNY 44.2M | 0.02 | 11.2% |
| 2022 | CNY 54.3M | 0.02 | 11.7% |
| 2021 | CNY 61.5M | 0.02 | 16.6% |
| 2020 | CNY 24.1M | 0.01 | - |
| 2019 | CNY 10.3M | 0.00 | 18.5% |
| 2018 | CNY 1.35B | 0.55 | 390.3% |
| 2017 | CNY 1.35B | 0.53 | 330.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on Apr 6, 2016.
Who owns Harbin Pharmaceutical Group Co Ltd
- Insiders 51.29%
- Institutions 0.59%
- Public & others 48.12%
- Shares outstanding 2.52B
- Free float 1.33B
Harbin Pharmaceutical Group Co Ltd company profile
- Company name
- Harbin Pharmaceutical Group Co Ltd
- Ticker
- 600664.SHG
- ISIN
- CNE0000009T3
- Exchange
- Shanghai Stock Exchange
- Listed since
- Feb 1, 1990
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10,039
- Fiscal year end
- December
- Address
- No. 7, Qunli Avenue, Harbin, China, 150070
- Phone
- 86 40 0900 1111
- Website
- hayao.com
About Harbin Pharmaceutical Group Co Ltd
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, antiviral and anti-infective, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, human erythropoietin injections, iron and vitamin B12 oral solutions, calcium, iron, and zinc oral solutions, ceftriaxone sodium injections, Qufenggutong gel ointment, GNC Vitapak nutritional pack, lacidipine tablets, GNC fish oil capsules, coenzyme Q10 and panthenol soft capsules, GNC children's liquid calcium magnesium zinc, penicillin sodium, acetaminophen and chlorpheniramine maleate granules, glucosamine chondroitin calcium tablets, ceftriaxone sodium for injection, GNC milk thistle extract tablets and capsules, and compound sulfamethoxazole oral tablets. The company is also involved in culture, science and technology, pharmaceutical commercial and industry, property, and investment activities. Harbin Pharmaceutical Group Co., Ltd. was founded in 1991 and is based in Harbin, China.
Harbin Pharmaceutical Group Co Ltd management
6- Mr. Chuanyou LuPresident & Director · born 1962
- Mr. Xiaodong MengVP, Secretary & Financial Director · born 1972
- Mr. Haitao JiangVice President · born 1982
- Mr. Jicheng XiaVice President · born 1979
- Mr. Bangdong LiVice President · born 1973
- Mr. Guangjun DiaoVice President · born 1976